Abstract: Electron beam powder bed fusion may be performed using waste powder from laser beam powder bed fusion by pre-heating a build chamber using stepped increases of electron beam current. To perform the pre-heating without smoking the powder, a plurality of predetermined interim temperatures, ranging from an ambient, resting temperature of the build chamber to a predetermined preheated temperature, are determined. A build plate within the build chamber is exposed to a plurality of streams of electrons, one at a time, while the build plate is surrounded by the waste powder. Each stream of electrons has a progressively increasing current, with the current being increased each time an actual temperature of the build chamber reaches or exceeds the next predetermined interim temperature. The actual temperature of the build chamber is monitored during the pre-heating, to compare the actual temperature of the build chamber to the plurality of predetermined interim temperatures.

Abstract: In an energy harvesting system, a power extraction circuit extracts electrical power from an environmental power source susceptible of providing a level of power that fluctuates. An electrical power storage device stores the electrical power extracted from the environmental power source by the power extraction circuit. A sensing circuit provides an indication of a level of power that the power extraction circuit can extract from the environmental power source. A controlled switch circuit electrically decouples the power extraction circuit from the electrical power storage device when the indication indicates that the level of power that the power extraction circuit can extract from the environmental power source is insufficient for the power extraction circuit to charge the electrical power storage device. This prevents leakage of harvested power.

Abstract: In an image sensor, a front-end circuit provides an output signal indicative of the amount of light in response to at least one input signal. The front-end circuit includes a transistor having a threshold voltage that affects a relationship between the output signal and the level of the detection quantity. This transistor has a biasing node via which a biasing voltage can be applied to a semiconductor region that affects the threshold voltage of the transistor. A replica of the front-end circuit receives at least one defined input signal, among which is a substitute of the detection quantity having a defined level. The replica is arranged in a control loop that controls the biasing voltage that is applied to the biasing node in the replica, so that the replica provides a defined output signal. This biasing voltage is then also applied to the biasing node in the front-end circuit.

Abstract: In an image sensor, a photo detector circuit applies a photo current to a capacitive node during a photo detection time interval. A front-end circuit comprises an input transistor having a control node that is coupled to the capacitive node. A switchable biasing arrangement puts the input transistor in a disabled state during the photo detection time interval. The input transistor is put in an enabled state after the photo detection time interval. This then causes the front-end circuit to provide an output signal that is representative of a voltage on the capacitive node after the photo detection time interval.

Abstract: In an image sensor, a photo detector circuit applies a photo current to a capacitive node during a photo detection time interval. A front-end circuit comprises an input transistor having a control node that is coupled to the capacitive node. A switchable biasing arrangement puts the input transistor in a disabled state during the photo detection time interval. The input transistor is put in an enabled state after the photo detection time interval. This then causes the front-end circuit to provide an output signal that is representative of a voltage on the capacitive node after the photo detection time interval.

Abstract: In an image sensor, a front-end circuit provides an output signal indicative of the amount of light in response to at least one input signal. The front-end circuit includes a transistor having a threshold voltage that affects a relationship between the output signal and the level of the detection quantity. This transistor has a biasing node via which a biasing voltage can be applied to a semiconductor region that affects the threshold voltage of the transistor. A replica of the front-end circuit receives at least one defined input signal, among which is a substitute of the detection quantity having a defined level. The replica is arranged in a control loop that controls the biasing voltage that is applied to the biasing node in the replica, so that the replica provides a defined output signal. This biasing voltage is then also applied to the biasing node in the front- end circuit.

Abstract: An ultra-low-power transconductance device is provided, (FIG. 1b, FIG. 1c), comprising a series connection of a transistor of a first channel type (A) and a transistor of a second channel type (B), the first channel type having a different polarity than the second channel type. The transistors each have a source, a drain and a gate. The source of the transistor of the first channel type (A) is coupled with the source of the transistor of the second channel type (B) and the drain of the transistor of the first channel type (A) is coupled with the gate of the transistor of the second channel type (B).

Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: An ultra-low-power transconductance device is provided, (FIG. 1b, FIG. 1c), comprising a series connection of a transistor of a first channel type (A) and a transistor of a second channel type (B), the first channel type having a different polarity than the second channel type. The transistors each have a source, a drain and a gate. The source of the transistor of the first channel type (A) is coupled with the source of the transistor of the second channel type (B) and the drain of the transistor of the first channel type (A) is coupled with the gate of the transistor of the second channel type (B).

Abstract: Sets of biomarker genes useful for monitoring exposure and response to anti-tumor agents that inhibit IMPDH and related biomolecules are disclosed along with methods for identifying such sets of genes, methods of using such sets to identify additional therapeutic agents as well as methods for stratifying patients into groups that are sensitive or resistant to such therapeutic agents. Methods of screening patients for recurrence of disease by monitoring changes in gene expression associated with malignancy are also described. The nucleotide sequence of such biomarkers are presented.

Abstract: The present invention provides novel polynucleotides encoding LTRPC3 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of LTRPC3 polypeptides, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Methods for the identification of disease-related gene sets and expression nprofiles, based on common chemical modulation using a specific chemical compound are disclosed.

Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Methods for the identification of disease-related gene sets and expression nprofiles, based on common chemical modulation using a specific chemical compound are disclosed.